Aldose reductase inhibitor fidarestat prevents diabetic ocular complications in spontaneously diabetic Torii rats

Open Diabetes Journal

Volumn 4, Issue SPEC. ISSUE 1, 2011, Pages 101-107

  Kakehashi, Akihiro ^a   Takezawa, Mikiko ^a   Toyoda, Fumihiko ^a   Kinoshita, Nozomi ^a   Kambara, Chiho ^a   Yamagami, Hiroko ^a   Kato, Noriaki ^b   Ishikawa, San e ^a   Kawakami, Masanobu ^a   Kanazawa, Yasunori ^c  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b SANWA KAGAKU KENKYUSHO CO LTD   (Japan)

^c Japan Diabetes Foundation   (Japan)

Author keywords

Cataract; Diabetic retinopathy; Fidarestat; Spontaneously diabetic Torii (SDT) rat; Vascular endothelial growth factor (VEGF)

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; CREATININE; FIDARESTAT; FRUCTOSE; GLUCOSE; GLUTATHIONE; GLYCOSYLATED HEMOGLOBIN; POLYOL; SORBITOL; VASCULOTROPIN;

AMINO ACID URINE LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATARACT; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; GLUCOSE BLOOD LEVEL; LOW DRUG DOSE; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RAT STRAIN; SIGNAL TRANSDUCTION; SPONTANEOUSLY DIABETIC TORII RAT; TISSUE LEVEL; WEIGHT CHANGE;

EID: 80455174143     PISSN: None     EISSN: 18765246     Source Type: Journal    
DOI: 10.2174/1876524601104010101     Document Type: Article

References (43)

1. Writing team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complication Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002; 287: 2563-9.
2. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-86.
3. Stratton IM, Kohner EM, Aldington SJ, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001; 44: 156-63.
4. Hotta N, Nakamura J, Sakakibara F, et al. Electroretinogram in sucrose-fed diabetic rats treated with an aldose reductase inhibitor or an anticoagulant. Am J Physiol 1997; 273: E965-71.
5. Robison WG Jr., Nagata M, Tillis TN, Laver N, Kinoshita JH. Aldose reductase and pericyte-endothelial cell contacts in retina and optic nerve. Invest Ophthalmol Vis Sci 1989; 30: 2293-9.
6. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997; 46: 1473-80.
7. Lee TS, MacGregor LC, Fluharty SJ, King GL. Differential regulation of protein kinase C and (Na,K)-adenosine triphosphatase activities by elevated glucose levels in retinal capillary endothelial cells. J Clin Invest 1989; 83: 90-4.
8. Nakamura J, Kato K, Hamada Y, et al. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 1999; 48: 2090-5.
9. Kuroki M, Voest EE, Amano S, et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest 1996; 98: 1667-5.
10. Altomare E, Grattagliano I, Vendemaile G, Micelli-Ferrari T, Signorile A, Cardia L. Oxidative protein damage in human diabetic eye: evidence of a retinal participation. Eur J Clin Invest 1997; 27: 141-7.
11. Hammes HP, Brownlee M, Lin J, Schleicher E, Bretzel RG. Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product Nepsilon-(carboxymethyl) lysine independently of glycohaemoglobin concentrations. Diabetologia 1999; 42: 603-7.
12. Hammes HP, Wellensiek B, Kloting I, Sickel E, Bretzel RG, Brownlee M. The relationship of glycaemic level to advanced glycation end-product (AGE) accumulation and retinal pathology in the spontaneous diabetic hamster. Diabetologia 1998; 41: 165-70.
13. Murata T, Nagai R, Ishibashi T, Inomuta H, Ikeda K, Horiuchi S. The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia 1997; 40: 764-9.
14. Dvornik E, Simard-Duquesne N, Krami M, et al. Polyol accumulation in galactosemic and diabetic rats: control by an aldose reductase inhibitor. Science 1973; 182: 1146-8.
15. Yeh LA, Rafford CE, Beyer TA, Hutson NJ. Effects of the aldose reductase inhibitor sorbinil on the isolated cultured rat lens. Metabolism 1986; 35: 4-9.
16. Sun W, Oates PJ, Coutcher JB, Gerhardinger C, Lorenzi M. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes 2006; 55: 2757-62.
17. Robinson WG, Jr., Laver NM, Jacot JL, et al. Diabetic-like retinopathy ameliorated with the aldose reductase inhibitor WAY-121,509. Invest Ophthalmol Vis Sci 1996; 37: 1149-56.
18. Okuda J, Yashima K, Inagaki K, Miwa I. Effects of an aldose reductase inhibitor, 1-[(p-bromophenyl)-sulfonyl]hydantoin, on cataract formation and tissue polyol levels in galactosemic rats. Chem Pharm Bull (Tokyo) 1985; 33: 2990-5.
19. Obrosova IG, Pacher P, Szabo C, et al. Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications. Diabetes 2005; 54: 234-42.
20. Obrosova IG, Minchenko AG, Vasupuram R, et al. Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes 2003; 52: 864-71.
21. Kato N, Yashima S, Suzuki T, Nakayama Y, Jomori T. Long-term treatment with fidarestat suppresses the development of diabetic retinopathy in STZ-induced diabetic rats. J Diabetes Complications 2003; 17: 374-9.
22. Robison WG, Jr., Kador PF, Kinoshita JH. Retinal capillaries: basement membrane thickening by galactosemia prevented with aldose reductase inhibitor. Science 1983; 221: 1177-9.
23. Frank RN, Keirn RJ, Kennedy A, Frank KW. Galactose-induced retinal capillary basement membrane thickening: prevention by Sorbinil. Invest Ophthalmol Vis Sci 1983; 24: 1519-24.
24. A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Sorbinil Retinopathy Trial Research Group. Arch Ophthalmol 1990; 108: 1234-44.
25. Hotta N, Toyota T, Matsuoka K, et al. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care 2001; 24: 1776-82.
26. D'Amato R, Wesolowski E, Smith LE. Microscopic visualization of the retina by angiography with high-molecular-weight fluorescein-labeled dextrans in the mouse. Microvasc Res 1993; 46: 135-42.
27. Kakehashi A, Saito Y, Mori K, et al. Characteristics of diabetic retinopathy in SDT rats. Diabetes Metab Res Rev 2006; 22: 455-61.
28. Guerrant GO, Moss CW. Determinations of monosaccharide as aldononitrite, o-methyleoxime, alditol, and cyclitol acetate derivatives by gas chromatography. Anal Chem 1984; 56: 633-8.
29. Shinohara M, Masuyama T, Kakehashi A. The spontaneously diabetic Torii (SDT) rat with retinopathy lesions resembling those of humans. In: Shafrir E, Ed. Animal models of diabetes.-frontiers in research.2nd ed. CRC Press, Boca Raton(FL): 2007; pp. 311-21.
30. Shinohara M, Masuyama T, Shoda T, et al. A new spontaneously diabetic non-obese Torii rat strain with severe ocular complications. Int J Exp Diabetes Res 2000; 1: 89-100.
31. Van Dam PS, Van Asbeck BS, Erkelens DW, Marx JJ, Gispen WH, Bravenboer B. The role of oxidative stress in neuropathy and other diabetic complications. Diabetes Metab Rev 1995; 11: 181-92.
32. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996; 19: 257-67.
33. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a causal antioxidant therapy. Diabetes Care 2003; 26: 1589-96.
34. Mitton KP, Dean PA, Dzialoszynski T, Xiong H, Sanford SE, Trevithick JR. Modelling cortical cataractogenesis. 13. Early effects on lens ATP/ADP and glutathione in the streptozotocin rat model of the diabetic cataract. Exp Eye Res 1993; 56: 187-98.
35. Ross WM, Creighton MO, Trevithick JR, Stewart-DeHaan PJ, Sanwal M. Modelling cortical cataractogenesis: VI. Induction by glucose in vitro or in diabetic rats: prevention and reversal by glutathione. Exp Eye Res 1983; 37: 559-73.
36. Sampathkumar R, Balasubramanyam M, Tara C, Rema M, Mohan V. Association of hypoglutathionemia with reduced Na+/K+ ATPase activity in type 2 diabetes and microangiopathy. Mol Cell Biochem 2006; 282: 169-76.
37. Miwa K, Nakamura J, Hamada Y, et al. The role of polyol pathway in glucose-induced apoptosis of cultured retinal pericytes. Diabetes Res Clin Pract 2003; 60: 1-9.
38. Suzuki S, Hinokio Y, Komatu K, et al. Oxidative damage to mitochondrial DNA and its relationship to diabetic complications. Diabetes Res Clin Pract 1999; 45: 161-8.
39. Park KS, Kim JH, Kim MS, et al. Effects of insulin and antioxidant on plasma 8-hydroxyguanine and tissue 8-hydroxydeoxyguanosine in streptozotocin-induced diabetic rats. Diabetes 2001; 50: 2837-41.
40. Kakimoto M, Inoguchi T, Sonta T, et al. Accumulation of 8-hydroxy-2'-deoxyguanosine and mitochondrial DNA deletion in kidney of diabetic rats. Diabetes 2002; 51: 1588-95.
41. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 1995; 92: 10457-61.
42. Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy. Br J Ophthalmol 1996; 80: 241-5.
43. Tolentino MJ, Miller JW, Gragoudas ES, Chatzistefanou K, Ferrara N, Adamis AP. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 1996; 114: 964-70.